<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092442</url>
  </required_header>
  <id_info>
    <org_study_id>CSG801.002-M</org_study_id>
    <nct_id>NCT01092442</nct_id>
  </id_info>
  <brief_title>CryoValve SG Pulmonary Human Heart Valve Post Clearance Study</brief_title>
  <acronym>SGPV</acronym>
  <official_title>CryoValve SG Pulmonary Human Heart Valve Post Clearance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CryoLife, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CryoLife, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect long-term follow-up data of the CryoValve SG
      Pulmonary Human Heart Valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CryoValve SG pulmonary human heart valve is recovered from deceased human donors, treated
      with the SynerGraft® process,which is designed to reduce the donor cells present on the
      graft. The valve is then cryopreserved for storage until use. Removing cells from the heart
      valve has been shown to reduce a component of the immune response after implant compared to a
      standard allograft valve. However, it is not known how this affects the long-term durability
      of the valve.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic Performance</measure>
    <time_frame>Most Recent follow-up (average of 3-6 years post implant)</time_frame>
    <description>Peak Pulmonary Gradient Mean Pulmonary Gradient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic Performance</measure>
    <time_frame>Most Recent Follow-up (average of 4 to 6 years post implant)</time_frame>
    <description>Pulmonary Insufficiency Grade</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>Since Implant of the Valve to a Maximum of 13.0 years</time_frame>
    <description>Evaluation of the following adverse events
Mortality (all cause and valve-related)
Reoperation/reintervention
Explant
Endocarditis
Structural valve deterioration (defined as &gt;40 mmHg peak pulmonary gradient or &gt;30 mmHg mean pulmonary gradient or moderately severe to severe pulmonary insufficiency)
Thrombosis
Thromboembolism (pulmonary embolism)
Non-structural dysfunction
Perivalvular leak
Bleeding
Hemolysis
Calcification</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">140</enrollment>
  <condition>Pulmonary Valve Stenosis</condition>
  <condition>Pulmonary Valve Insufficiency</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Retrospective Patients</arm_group_label>
    <description>Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective Patients</arm_group_label>
    <description>Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiogram</intervention_name>
    <description>Patients will have a yearly echocardiogram after enrollment in the study.</description>
    <arm_group_label>Retrospective Patients</arm_group_label>
    <arm_group_label>Prospective Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients who have had a CryoValve SG Pulmonary Human Heart Valve implanted in
        the pulmonary position for right ventricular outflow tract (RVOT) reconstruction or as part
        of the Ross procedure at selected institutions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        • Retrospective Patients

        o Sequential patients implanted with a CryoValve SG Pulmonary Human Heart Halve as a Ross
        or RVOT reconstruction between February 2000 and March 2004 who were included in the 510(k)
        data collection will be identified using the following general criteria to aid in selection
        of patients who are most likely to provide adequate follow-up data: Patient is alive and
        the implanted valve is still in place (has not been explanted).

        Patient is still under the care of the implanting institution or the implanting surgeon.

        Patient was identified as previously providing data for at least one echocardiographic
        follow-up assessment at a minimum of one year post-implant.

          -  Additionally, prospective enrolling centers will have the option to enroll
             retrospective patients. At these centers, all consecutive patients identified from
             valve implant data at CryoLife, implanted with a CryoValve SG Pulmonary Valve as a
             valved pulmonary valve prior to Clearance in 2008 will be targeted for inclusion in
             the retrospective patient data collection.

             • Prospective Patients

          -  Sequential patients implanted with a CryoValve SG Pulmonary Human Heart Halve as a
             Ross or RVOT reconstruction after FDA 510(k) clearance in February 2008 at selected
             institutions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott B Capps, MS</last_name>
    <role>Study Director</role>
    <affiliation>CryoLife, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Pediatric Cardiology Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Health and Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgeons and Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Healthcare System of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brown JW, Elkins RC, Clarke DR, Tweddell JS, Huddleston CB, Doty JR, Fehrenbacher JW, Takkenberg JJ. Performance of the CryoValve SG human decellularized pulmonary valve in 342 patients relative to the conventional CryoValve at a mean follow-up of four years. J Thorac Cardiovasc Surg. 2010 Feb;139(2):339-48. doi: 10.1016/j.jtcvs.2009.04.065.</citation>
    <PMID>20106397</PMID>
  </reference>
  <reference>
    <citation>Konuma T, Devaney EJ, Bove EL, Gelehrter S, Hirsch JC, Tavakkol Z, Ohye RG. Performance of CryoValve SG decellularized pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg. 2009 Sep;88(3):849-54; discussion 554-5. doi: 10.1016/j.athoracsur.2009.06.003.</citation>
    <PMID>19699910</PMID>
  </reference>
  <reference>
    <citation>Hawkins JA, Hillman ND, Lambert LM, Jones J, Di Russo GB, Profaizer T, Fuller TC, Minich LL, Williams RV, Shaddy RE. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg. 2003 Jul;126(1):247-52; discussion 252-3.</citation>
    <PMID>12878962</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>November 2, 2015</results_first_submitted>
  <results_first_submitted_qc>November 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 9, 2015</results_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Valve</keyword>
  <keyword>Right Ventricular Outflow Tract Reconstruction</keyword>
  <keyword>Ross Procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Stenosis</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Retrospective Patients</title>
          <description>Retrospective Patients: These patients had the CryoValve SG Pulmonary Valve implanted prior to the February 2008 clearance of the valve.</description>
        </group>
        <group group_id="P2">
          <title>Prospective Patients</title>
          <description>Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Retrospective Patients</title>
          <description>Retrospective Patients: These patients had the CryoValve SG Pulmonary Valve implanted prior to the February 2008 clearance of the valve.</description>
        </group>
        <group group_id="B2">
          <title>Prospective Patients</title>
          <description>Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="14.1"/>
                    <measurement group_id="B2" value="26.2" spread="21.1"/>
                    <measurement group_id="B3" value="20.2" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamic Performance</title>
        <description>Peak Pulmonary Gradient Mean Pulmonary Gradient</description>
        <time_frame>Most Recent follow-up (average of 3-6 years post implant)</time_frame>
        <population>The number of participants was limited to those participants with a hemodynamic measurement provided. Therefore, the total number in each group is less than the total participants in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Retrospective Ross</title>
          </group>
          <group group_id="O2">
            <title>Prospective Ross</title>
          </group>
          <group group_id="O3">
            <title>Retrospective Right Ventricular Outflow Tract (RVOT)</title>
          </group>
          <group group_id="O4">
            <title>Prospective RVOT</title>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance</title>
          <description>Peak Pulmonary Gradient Mean Pulmonary Gradient</description>
          <population>The number of participants was limited to those participants with a hemodynamic measurement provided. Therefore, the total number in each group is less than the total participants in each group.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak Pulmonary Gradient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="16.0"/>
                    <measurement group_id="O2" value="13.5" spread="10.9"/>
                    <measurement group_id="O3" value="21.2" spread="11.4"/>
                    <measurement group_id="O4" value="21.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Pulmonary Gradient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="8.3"/>
                    <measurement group_id="O2" value="7.5" spread="5.7"/>
                    <measurement group_id="O3" value="12.3" spread="6.5"/>
                    <measurement group_id="O4" value="11.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamic Performance</title>
        <description>Pulmonary Insufficiency Grade</description>
        <time_frame>Most Recent Follow-up (average of 4 to 6 years post implant)</time_frame>
        <population>The number of participants was limited to those participants with a hemodynamic measurement provided. Therefore, the total number in each group is less than the total participants in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Retrospective Ross</title>
          </group>
          <group group_id="O2">
            <title>Prospective Ross</title>
          </group>
          <group group_id="O3">
            <title>Retrospective RVOT</title>
          </group>
          <group group_id="O4">
            <title>Prospective RVOT</title>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Performance</title>
          <description>Pulmonary Insufficiency Grade</description>
          <population>The number of participants was limited to those participants with a hemodynamic measurement provided. Therefore, the total number in each group is less than the total participants in each group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trivial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Assessment</title>
        <description>Evaluation of the following adverse events
Mortality (all cause and valve-related)
Reoperation/reintervention
Explant
Endocarditis
Structural valve deterioration (defined as &gt;40 mmHg peak pulmonary gradient or &gt;30 mmHg mean pulmonary gradient or moderately severe to severe pulmonary insufficiency)
Thrombosis
Thromboembolism (pulmonary embolism)
Non-structural dysfunction
Perivalvular leak
Bleeding
Hemolysis
Calcification</description>
        <time_frame>Since Implant of the Valve to a Maximum of 13.0 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ross Patients</title>
            <description>Retrospective and Prospective Patients that had the CryoValve SG Pulmonary Human Heart Valve implanted as a part of the Ross Procedure</description>
          </group>
          <group group_id="O2">
            <title>RVOT Reconstruction Patients</title>
            <description>Retrospective and Prospective Patients that had the CryoValve SG Pulmonary Human Heart Valve implanted for RVOT reconstruction procedures</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Assessment</title>
          <description>Evaluation of the following adverse events
Mortality (all cause and valve-related)
Reoperation/reintervention
Explant
Endocarditis
Structural valve deterioration (defined as &gt;40 mmHg peak pulmonary gradient or &gt;30 mmHg mean pulmonary gradient or moderately severe to severe pulmonary insufficiency)
Thrombosis
Thromboembolism (pulmonary embolism)
Non-structural dysfunction
Perivalvular leak
Bleeding
Hemolysis
Calcification</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10-Year Freedom from Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Valve-Related Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Reoperation/Reintervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from SVD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Non-structural Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Perivalvular Leak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Hemolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-Year Freedom from Calcification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Since Implant of the Valve to a Maximum of 13 years</time_frame>
      <desc>Other Adverse Events were not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Ross Patients</title>
          <description>Retrospective and Prospective Patients that had the CryoValve SG Pulmonary Human Heart Valve implanted as a part of the Ross Procedure</description>
        </group>
        <group group_id="E2">
          <title>RVOT Reconstruction Patients</title>
          <description>Retrospective and Prospective Patients that had the CryoValve SG Pulmonary Human Heart Valve implanted for RVOT reconstruction procedures</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Explant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Reoperation/Reintervention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI can not publish any results or data arising from the study except with the institution's approval and sponsor's written consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott B. Capps, MS</name_or_title>
      <organization>CryoLife, Inc.</organization>
      <phone>800-438-8285</phone>
      <email>clinicaltrialregistration@cryolife.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

